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Abstract 
Background: Fractures in Gaucher disease type 1 (GD1) patients cause significant morbidity. Fracture risk may be 
decreased by enzyme replacement therapy (ERT) but not eliminated. When considering initiation of treatment, it is 
useful to know to what extent fixed patient-specific factors determine risk for future fractures beyond standard risk 
factors that change with time and treatment, such as decreased bone mineral density. We developed a tool called the 
GRAF score (Gaucher Risk Assessment for Fracture) that applies 5 widely available characteristics (sex, age at treatment 
initiation [ATI], time interval between diagnosis and treatment initiation, splenectomy status, history of pre-treatment 
bone crisis) and provides a practical method to assess future fracture risk when imiglucerase ERT is initiated.
Methods: Inclusion criteria: GD1 patients in the International Collaborative Gaucher Group Gaucher Registry as 
of September 2019 initially treated with alglucerase/imiglucerase; known splenectomy status; at least one skeletal 
assessment on treatment (3216 of 6422 patients). Data were analyzed by ATI group (< 18, ≥ 18 to < 50, or ≥ 50 years of 
age) using Cox proportional hazards regression with all 5 risk factors included in the multivariable model. A composite 
risk score was calculated by summing the contribution of each parameter weighted by the strength of its association 
(regression coefficient) with fracture risk.
Results: Patients were followed from the date of treatment initiation (or age 18 years for patients if treatment started 
earlier) to the date of first adult fracture (n = 288 first fracture endpoints), death, or end of follow-up. The GRAF score 
for each ATI group was associated with a 2.7-fold increased risk of adult fracture for each one-point increase (p < 0.02 
for < 18 ATI, p < 0.0001 for ≥ 18 to < 50 ATI and ≥ 50 ATI).
Conclusions: The GRAF score is a tool to be used with bone density and other modifiable, non-GD-specific risk fac-
tors (e.g. smoking, alcohol intake, frailty) to inform physicians and previously untreated GD1 patients about risk for a 
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Introduction
Gaucher disease (GD) is a lysosomal storage dis-
ease caused by mutations in the glucocerebrosidase 
gene (GBA1) that leads to deficient lysosomal acid 
β-glucosidase (glucocerebrosidase, EC 3.2.1.21) activity. 
GD has classically been categorized into 3 main types 
(GD types 1, 2 and 3). The majority of cases are classi-
fied as GD type 1 (GD1), which is characterized by a lack 
of early-onset central nervous system disease, unlike GD 
types 2 and 3. Patients with GD1 can present with hepat-
osplenomegaly, anemia, thrombocytopenia, bone pain, 
growth failure in childhood and a number of additional 
manifestations [1, 2]. Skeletal manifestations of GD1 are 
significant sources of pain and disability, including bone 
pain, bone crisis, osteonecrosis, lytic lesions, and fracture 
[3–7]. GD1 affects both supportive bone tissue and bone 
marrow.
GD-related changes at the cellular level contribute to 
decreased bone accretion in children, decreased peak 
bone mass in young adults, and the further development 
of low bone mass with age. Low bone mass is the strong-
est factor affecting fracture risk in the general popu-
lation and is also associated with fracture in GD [6, 8]. 
Some characteristics distinguish GD1 fractures from the 
general population. The most common site of fracture 
in GD1 is the spine followed by the hip and appendicu-
lar skeleton whereas the hip is the most common site of 
post-menopausal osteoporosis [7]. Other factors specific 
to GD1, such as cortical bone thinning, osteolytic lesions 
and focal disruption of bone architecture, may be asso-
ciated with fracture [3, 6, 7, 9]. A direct evaluation of 
clinical risk factors for fracture in GD, other than bone 
mineral density (BMD), is thus warranted.
Fractures are known to cause morbidity and reduced 
quality of life in GD1 patients [3, 10]. In a previous study 
of 1698 GD1 patients enrolled in the International Col-
laborative Gaucher Group (ICGG) Gaucher Registry 
(NCT00358943), 15% had fractures [1]. In a multi-center 
study in the United Kingdom (UK), 28% reported fragility 
fractures [10]. In a cohort of 105 adult GD1 patients in 
France, 18% had non-vertebral fractures and there was a 
15% prevalence of vertebral fractures [11]. Non-vertebral 
fractures were significantly greater in splenectomized 
patients, similar to results from the UK study. The mean 
age at vertebral fracture was 47 years with a range of 29 
to 70 years.
Studies on fractures in patients with GD have improved 
our understanding of the risk factors for fracture. As with 
the general population [12], a significant determinant of 
fracture risk in GD is bone density as measured by dual 
energy X-ray absorptiometry (DXA), with a 5.55 times 
higher risk of fracture at any site when the spine Z-score 
is less than or equal to  −1 [5]. This study exposed a 
lower-threshold DXA bone density for fracture compared 
to the general population suggesting that additional GD-
specific factors exist. Bone disease in GD patients can be 
occult and aggravated by previous splenectomy [13] and 
delays in diagnosis and treatment initiation  [14]. Thus, 
significant bone disease may be present by the time dis-
ease-modifying therapy is started [10, 11, 14–16].
Although DXA scanning is recommended in several 
GD management guidelines [17], not all GD1 patients 
worldwide have ready access to DXA. The impact of 
common demographic features readily available at clinic 
visits (e.g. sex, year of birth, treatment status, and sple-
nectomy status) have only been assessed in smaller 
studies [5]. The aim of this study, therefore, was to cre-
ate a composite risk score assessment (the Gaucher Risk 
Assessment for Fracture [GRAF]) as a clinical tool to be 
used with other modifiable, non-GD-specific risk factors 
(e.g. smoking, alcohol intake, frailty) to inform physicians 
and previously untreated adult GD1 patients about risk 
for a future fracture after starting imiglucerase. While 
there are risk fracture scores (e.g., FRAX® [18]) available 
for the general population, a tool specific to GD-related 
factors would be additionally beneficial for the manage-
ment of GD1 patients.
Results
Patient disposition for study population
As of 06 September 2019, 3216 (50.1%) of 6422 patients 
in the ICGG Gaucher Registry met all inclusion and no 
exclusion criteria for the study. Excluded patients: 865 
(13.5%) patients were not specifically reported in the 
Registry as diagnosed as GD1; 191 (3.0%) patients had no 
diagnosis date; 1031 (16.1%) were excluded because treat-
ment status was unknown or they were reported as never 
treated; 502 (7.8%) patients’ initial treatment was not 
imiglucerase; 16 (0.2%) patients had no recorded splenec-
tomy status and 33 (0.5%) splenectomized patients did 
not have a splenectomy date; 524 (8.2%) patients did not 
have a complete medical history or at least one skeletal 
future fracture after starting imiglucerase regardless of whether there is an eventual switch to an alternative ERT or to 
substrate reduction therapy. GRAF can also help predict the extent that fracture risk increases if initiation of treatment 
is further delayed.
Keywords: Gaucher disease, Fracture, Imiglucerase, Enzyme replacement therapy, Risk factor
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assessment; 44  (0.7%) patients with a reported fracture 
did not have a fracture date.
Of the 3216 study population patients, 568 were 
excluded from the fracture risk analysis population 
because they reported a first fracture prior to age 18 
(n = 104), reported a first fracture prior to initiation of 
treatment (n = 125), or had no follow-up after age 18 
(n = 339). Thus, the fracture risk analysis population was 
2648 patients of whom 288 had a first-time fracture in 
adulthood after imiglucerase was started.
Demographic characteristics and distribution of first 
fracture location among patients with fracture in the total 
study population
Summary data on the demographic and clinical charac-
teristics of patients with fracture (pediatric and adult) 
and the location of first fractures (pediatric and adult) are 
shown in supplemental tables, stratified by whether first 
fracture occurred before or after initiation of imigluc-
erase (Additional file 2: Table S-II, Additional file 3: Table 
S-III, Additional file 4: Table S-IV, Additional file 5: Table 
S-V).
Baseline demographic and clinical characteristics 
among patients with and without fracture in the fracture 
risk analysis population
The total person-years of follow-up (i.e., total follow-up 
time across all patients at risk of fracture) for the analy-
sis population was 30,666 person-years, with individual 
patients being followed for a median (25%, 75%) of 10.9 
(4.6, 17.8) years. During this time, 288 first fractures in 
adulthood were reported, resulting in an overall inci-
dence rate of 9.4  fractures per 1000 person-years. Fifty 
of the fractures occurred after switching from imigluc-
erase to another therapy and 84 fractures occurred on or 
after 25 June 2009 (the beginning of a temporary imiglu-
cerase shortage). The mean (standard deviation [SD]) age 
of first fracture during adulthood for those 288 patients 
with fracture was 49.2 (16.6) years and ranged from 18.1 
to 90.4 years (Additional file 3: Table S-III). Additionally, 
the frequencies of multiple fractures reported on the first 
fracture date and of subsequent fractures reported after 
the first fracture date are shown in supplemental materi-
als (Additional file 6: Table S-VI).
Sex, genotype (using legacy nomenclature: N370S 
homozygous, all other genotypes, unknown genotype) 
and other baseline demographic and clinical character-
istics for the fracture risk analysis population (with and 
without fracture during follow-up) by ATI cohort are 
summarized in Table  1. The majority of patients in the 
analysis population were in the ≥ 18 to < 50  year ATI 
cohort and did not report a fracture in adulthood. Within 
each ATI cohort, patients with fracture tended to be 
older at treatment initiation, have a longer time interval 
between diagnosis and treatment initiation, and were 
more likely to have a history of splenectomy and bone 
crisis prior to treatment initiation than those without 
fracture. In all ATI cohorts, women, pre- and post-meno-
pausal, had more fractures than men.
Fracture risk analyses
The results of the Cox proportional hazard regression by 
ATI cohort for all types of fractures and spinal fractures 
separately are presented in Fig.  1 as Forest plots. The 
multivariable model for total fracture risk showed vari-
ation in statistical significance and magnitude of the haz-
ard ratios for the 5 individual risk factors across the 3 ATI 
cohorts. For the < 18  year ATI cohort, all types of frac-
ture (panel A), no individual factor was statistically sig-
nificant, although the overall risk score was statistically 
significant (p < 0.05). For the ≥ 18 to < 50 year ATI cohort, 
all types of fracture (panel B), all factors except sex were 
statistically significant (p < 0.05). Older age at treatment 
initiation, longer interval between diagnosis and treat-
ment initiation, having been splenectomized, and having 
bone crisis prior to treatment initiation were associated 
with greater fracture risk. For the ≥ 50 year ATI cohort, 
all types of fracture (panel C), sex, age at treatment ini-
tiation, time interval between diagnosis and treatment, 
and having had a bone crisis were statistically significant 
factors (p < 0.01); splenectomy status was not statistically 
significant. The individual risk factor estimates within 
each ATI cohort for spinal fracture were similar in mag-
nitude and direction as for total fracture risk; however, 
several factors did not reach statistical significance, likely 
due to fewer spinal fracture endpoints (Fig.  1, panels D 
to F).
Summary statistics of the length of follow-up and the 
GRAF score values as well as the relationship between 
GRAF score and fracture risk are presented by ATI 
cohort in Table 2. Median follow-up time was 7.9, 13.8, 
and 8.2  years in the < 18, ≥ 18 to < 50, and ≥ 50  year ATI 
cohorts, respectively. The median GRAF score values in 
the risk analysis population from the younger ATI cohort 
to the older ATI cohort were 0.7, 1.2, and 2.8, respec-
tively. The median GRAF score values for the subset of 
patients with fracture in each ATI cohort (youngest to 
oldest) were 0.8, 1.5, and 3.1, respectively.
Each 1-point increase in GRAF score was associated 
with a 2.7-fold increased risk of first fracture (all types, 
p < 0.05) in adulthood for all 3 ATI cohorts (Table 2). An 
approximately 3- to 4-fold increased risk of spinal frac-
ture was associated with each 1-point increase in GRAF 
score for all 3 ATI cohorts (Hazard Ratios = 2.84 to 3.87), 
which was significant (p < 0.001) for the 2 older ATI 
cohorts but not for the youngest ATI cohort (p = 0.06).
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The cumulative incidence function plots (Fig.  2) illus-
trate the increasing probability of fracture over time 
based upon whether a patient’s GRAF score falls in the 
lower, middle, or upper third (i.e., tertiles) of the risk 
score values within each ATI cohort. Gray’s test, which 
assesses whether the cumulative incidence curves 
differed by GRAF score tertile, reached statistical sig-
nificance for the 18 to < 50 ATI cohort (p < 0.0001) and 
the ≥ 50  year ATI cohort (p = 0.0001). It was not statis-
tically significant, however, for the < 18  year ATI cohort 
(p = 0.13). For the < 18  year ATI cohort, the 10-year 
probability of fracture post-treatment initiation for the 
Table 1 Demographic and clinical characteristics in the fracture risk analysis population by ATI and fracture status
ATI = Age at treatment initiation; GD1 = Gaucher disease type 1
* Excludes patients from total study sample with first fracture prior to treatment initiation, first fracture prior to age 18, and patients whose follow-up did not extend 
past age 18 years













Number of patients, n
33 623 167 1318 88 419
Sex, n (%)
 Male 14 (42.4) 297 (47.7) 72 (43.1) 569 (43.2) 30 (34.1) 241 (57.5)
 Female 19 (57.6) 326 (52.3) 95 (56.9) 749 (56.8) 58 (65.9) 178 (42.5)
Age at GD1 diagnosis, years
 Mean (SD) 8.3 (4.64) 7.0 (4.33) 20.5 (13.44) 23.2 (12.65) 45.7 (18.26) 38.8 (20.45)
 Median (25th, 
75th)
6.9 (4.6, 11.8) 6.1 (3.6, 10.0) 20.8 (7.5, 29.3) 23.5 (12.8, 32.6) 50.1 (32.9, 58.3) 39.8 (23.2, 55.3)
 Range 2.9, 17.6 0.0, 17.4 0.0, 49.3 0.0, 49.7 0.5, 81.8 2.3, 78.9
Age at imiglucerase initiation, years
 Mean (SD) 12.0 (4.61) 10.0 (4.48) 36.6 (8.22) 33.8 (9.03) 60.5 (8.00) 60.9 (8.32)
 Median (25th, 
75th)
14.1 (8.3, 15.2) 10.2 (6.1, 13.8) 37.5 (30.3, 43.7) 33.8 (26.5, 41.4) 59.0 (53.8, 65.6) 59.3 (54.4, 65.7)
 Range 3.1, 17.9 0.2, 18.0 18.3, 49.9 18.0, 50.0 50.0, 84.1 50.2, 84.2
Time interval between diagnosis and imiglucerase initiation, years
 Mean (SD) 3.7 (4.36) 2.9 (3.79) 16.1 (12.09) 10.6 (11.02) 14.9 (15.95) 22.1 (18.59)
 Median (25th, 
75th)
0.9 (0.3, 7.7) 1.0 (0.3, 4.6) 17.5 (2.9, 25.0) 6.8 (0.7, 18.0) 8.9 (0.8, 26.7) 18.4 (1.4, 39.1)
 Range 0.1, 12.9 0.0, 16.6 0.0, 44.0 0.0, 46.5 0.0, 61.4 0.0, 60.6
Genotype, n (%)
 N370S/N370S 6 (18.2) 65 (10.4) 35 (21.0) 309 (23.4) 43 (48.9) 166 (39.6)
 All other geno-
types
24 (72.7) 481 (77.2) 116 (69.4) 775 (58.8) 34 (38.6) 179 (42.7)
 Unknown geno-
type
3 (9.1) 77 (12.4) 16 (9.6) 234 (17.8) 11 (12.5) 74 (17.7)
Splenectomized prior to or on treatment initiation date, n (%)
 No 27 (81.8) 567 (91.0) 88 (52.7) 942 (71.5) 56 (63.6) 299 (71.4)
 Yes 6 (18.2) 56 (9.0) 79 (47.3) 376 (28.5) 32 (36.4) 120 (28.6)
Age at splenectomy, years
 n 6 56 79 376 32 120
 Mean (SD) 8.7 (4.84) 7.7 (3.97) 17.5 (11.27) 19.4 (10.74) 27.2 (13.78) 36.6 (16.62)
 Median (25th, 
75th)
8.3 (3.8, 12.6) 7.5 (4.3, 10.1) 14.1 (8.0, 25.3) 18.5 (10.4, 26.5) 27.2 (14.2, 37.1) 37.8 (23.0, 50.1)
 Range 3.7, 15.6 2.1, 17.3 1.7, 45.0 1.5, 48.8 5.0, 57.1 4.5, 72.9
Bone crisis reported prior to or on treatment initiation date, n (%)
 No 30 (90.9) 555 (89.1) 134 (80.2) 1201 (91.1) 77 (87.5) 398 (95.0)
 Yes 3 (9.1) 68 (10.9) 33 (19.8) 117 (8.9) 11 (12.5) 21 (5.0)
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a  Total Fracture Risk: <18 Years Cohort
b Total Fracture Risk: ≥18 to <50 Years Cohort
TOTAL FRACTURE RISK
Risk Score Model
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Fig. 1 Total GRAF Score by ATI Cohort. The total risk score (Gaucher Risk Assessment for Fracture [GRAF] score) and the individual risk factor 
estimates from the Cox proportional hazards regression for first fracture (any type) in adulthood after treatment initiation are plotted by each age at 
treatment initiation (ATI) cohort in panels A through C. Panel A includes the forest plots for the < 18 years ATI cohort. Panel B includes the forest plots 
for the ≥ 18 to < 50 years ATI cohort. Panel C includes the forest plots for the ≥ 50 years ATI cohort. Panels D through F are the corresponding forest 
plots of the GRAF score and individual risk factor estimates for the secondary spinal fractures analyses. CI = confidence interval; Dx = diagnosis; 
NA = not applicable; Tx = treatment
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c Total Fracture Risk: ≥50 Years Cohort
d Spinal Fracture Risk: <18 Years Cohort
TOTAL FRACTURE RISK
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e Spinal Fracture Risk: ≥18 to <50 Years Cohort
f Spinal Fracture Risk: ≥50 Years Cohort
SPINAL FRACTURE RISK
Risk Score Model
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first, second, and third tertile was 2.5%, 5.8%, and 8.7%, 
respectively. For the ≥ 18 to < 50  years ATI cohort, the 
10-year probability of fracture post-treatment initiation 
for each tertile was 4.6%, 5.6%, and 13.6%, respectively. 
For the ≥ 50  years ATI cohort, the 10-year probability 
of fracture post-treatment initiation for each tertile was 
10.1%, 15.0%, and 25.5%, respectively.
The overall performance of the fracture risk model 
for predicting fractures as assessed by the inte-
grated area under the curve (AUC) analyses was 0.62 for 
the < 18  years ATI cohort, 0.64 for the ≥ 18 to < 50  years 
ATI cohort, and 0.65 for the ≥ 50 years ATI cohort. Inte-
grated AUCs were slightly higher for the spinal frac-
ture risk model for all ATI cohorts (0.67, 0.68, and 0.67, 
respectively).
Discussion
Traditional skeletal therapeutic goals for patients with 
GD1 concentrated on alleviation of bone pain, pre-
vention of bone crises and osteonecrosis, and correc-
tion of osteopenia [19]. Many patients have now been 
treated for over 20 years and there is interest in formu-
lating long-term therapeutic goals that emphasize posi-
tive functional outcomes. Such goals for the skeleton 
include maintenance of normal mobility and ability to 
exercise, and prevention of fractures and joint replace-
ment [20]. Unfortunately, GD1 patients continue to 
suffer fractures as well as osteonecrosis despite years of 
otherwise effective ERT [21, 22]. The likelihood of post-
ERT treatment bone complications is only partially 
predicted by either initial or serial GD disease severity 
scores (DS3) in which DXA score is a highly weighted 
component [22]. We investigated whether there are 
determinants for fracture other than DXA that can be 
easily identified when ERT is initiated and are of prog-
nostic value for both treating physicians and patients.
We created a composite picture of fracture risk 
using the extensive data available in the large popula-
tion of GD1 patients in the ICGG Gaucher Registry. 
The GRAF score uses variables easily accessible to the 
clinician and provides a tool to assess the relative risk 
of fracture within the GD1 population that may assist 
in management decisions. The current analyses com-
bine important fracture risk factors relevant to the 
GD1 patient population and examine the impact of 
each factor, in the context of the other factors, through 
multivariable modeling and the calculation of a regres-
sion coefficient-weighted additive risk score. All types 
of first fractures occurring during adulthood and after 
initiation of imiglucerase treatment were evaluated for 
the association between the composite GRAF score and 
fracture risk. We limited our analysis of fracture risk 
to adults because the causes and anatomical distribu-
tion of fracture in children are different from those in 
adults. Patients who were never treated with ERT were 
Table 2 Duration of follow-up, GRAF score, and association of GRAF score with fracture risk, by ATI
Abbreviations: ATI = age at treatment initiation; CI = confidence interval; GRAF = Gaucher Risk Assessment for Fracture; HR = hazard ratio
1 HR and 95% CI estimated using Cox proportional hazards regression from age at treatment initiation (or age 18 years for patients initiating therapy prior to 18 years) 
to first fracture in adulthood, death, or end of follow-up. For each 1 unit increase in GRAF score, the fracture risk increases by 272% (HR = 2.72 across all ATI cohorts)
N Years of follow-up GRAF score GRAF score association with fracture  risk1
Median (25%, 75%) Median (25%, 75%) HR (95% CI), p-value
ATI < 18 years cohort
 Total sample 656 7.9 (3.5, 13.9) 0.7 (0.4, 1.0)
 Patients w/ any type of fracture 33 4.5 (2.3, 8.6) 0.8 (0.7, 1.1) All types of fracture
2.72 (1.14, 6.50), 0.0246
 Patients w/spinal fracture 12 4.4 (1.3, 6.6) 0.9 (0.7, 1.2) Spinal fracture
3.87 (0.92, 16.20), 0.0643
ATI ≥ 18 to < 50 years cohort
 Total sample 1485 13.8 (5.7, 20.1) 1.2 (0.9, 1.6)
 Patients w/ any type of fracture 167 6.4 (2.0, 13.7) 1.5 (1.2, 1.9) All types of fracture 
2.72 (2.06, 3.58), < 0.0001
 Patients w/spinal fracture 61 6.0 (2.0, 12.9) 1.5 (1.3, 2.0) Spinal fracture 
3.44 (2.20, 5.38), < 0.0001
ATI ≥ 50 years cohort
 Total sample 507 8.2 (4.1, 14.3) 2.8 (2.3, 3.2)
 Patients w/any type of fracture 88 4.8 (1.7, 9.4) 3.1 (2.7, 3.6) All types of fracture 
2.72 (1.92, 3.84), < 0.0001
 Patients w/spinal fracture 34 4.9 (1.1, 10.6) 3.1 (2.7, 3.6) Spinal fracture 
2.84 (1.62, 4.99), 0.0003
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Fig. 2 Cumulative incidence of total fracture by tertile of Gaucher Risk Assessment for Fracture (GRAF) score and by age at treatment initiation (ATI) 
cohort. For each tertile of the risk score, the cumulative incidence function (CIF) is plotted for all types of fracture. The CIF indicates the probability 
of a patient experiencing any type of fracture over time. The p-value from Gray’s Test indicates whether there is a significant difference (alpha level 
of < 0.05) between the 3 curves overall. Panel A includes the CIFs for the < 18 years ATI cohort; panel B includes the CIFs for the ≥ 18 to < 50 years 
ATI cohort; panel C include the CIFs for the ≥ 50 years ATI cohort. Follow-up starts at age 18 years for patients < 18 years at treatment initiation, and 
at age of treatment initiation for patients ≥ 18 years. The maximum value for the y-axis has been truncated from 1.0 to 0.6 as none of the CIFs went 
above 0.6
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excluded as they generally represent a distinct group 
with mild disease; however, the pre-treatment history 
of treated patients did inform the analysis. First spi-
nal fractures during adulthood were also analyzed in 
a secondary analysis. It is important to note that com-
parisons of GRAF scores between ATI cohorts are not 
appropriate because the scores are based on the relative 
importance of the risk factors within each ATI cohort, 
and do not represent absolute measures such as inci-
dence rate or cumulative incidence.
The well-recognized impact of age on fracture risk, 
particularly in post-menopausal women [23, 24] is 
accounted for by creating 3 cohorts based upon the age 
at which the patient first initiated imiglucerase treat-
ment: < 18, ≥ 18 to < 50, and ≥ 50  years. In this  popu-
lation  of GD1 patients, the average age of fracture 
(49.2 years) indicates that GD may accelerate the burden 
of fracture risk to occur sooner. Furthermore, the over-
all incidence rate of 9.4 fractures per 1000 person-years 
observed in our GD1 population is substantially greater 
than an age-adjusted incidence of approximately 1  per 
1000 person-years for hip, vertebral and wrist fractures 
in a predominately white non-GD population from Min-
nesota USA [25]. The nearly 10-fold increase in fracture-
incidence in our cohort of imiglucerase-treated patients 
also suggests that there are determinants specific to GD 
and the GD treatment journey that contribute to fracture 
risk. Our analysis identified 5 elements that may con-
tribute to a high fracture risk in GD1 patients: sex, ATI, 
time between GD diagnosis and initiation of treatment, 
pre-treatment history of bone crisis, and pre-treatment 
splenectomy. After adjustment for all other factors in the 
multivariable model, the significance of each of these fac-
tors varied by ATI cohort. In the ATI < 18  year cohort, 
none of the individual factors were a significant indicator 
of fracture risk. In the middle cohort (ATI ≥ 18- < 50 y), 
all factors save sex were significant. In the ATI ≥ 50 year 
cohort, sex, age at treatment initiation, interval between 
diagnosis and treatment initiation, and history of bone 
crisis were significant factors; history of splenectomy was 
not significant in this subgroup.
Delayed initiation of treatment after diagnosis was con-
sistently associated with increased risk for fracture in all 
patients who were older than 18 years when imiglucerase 
was begun. There was a 16 to 20% greater risk for fracture 
for every 10-year increase in duration between diagnosis 
and treatment initiation (hazard ratio: 1.16–1.20) (Fig. 1, 
panels B and C). In the patients in whom imiglucerase 
was begun before age 18 years, the interval between diag-
nosis and treatment is generally shorter than in the older 
patients [26]. There was no relationship between the 
time interval between diagnosis and initiation of treat-
ment and fracture risk among patients treated before age 
18. Ten years ago, data from the ICGG Gaucher Registry 
indicated that a delay in ERT initiation in excess of two 
years from diagnosis was associated with a significantly 
greater risk of developing osteonecrosis despite continu-
ing treatment [27]. Our study is the first demonstration 
of delays in instituting ERT in GD1 patients whose dis-
ease severity ultimately warrants therapeutic interven-
tion being associated with a sustained risk for future 
fractures. This risk increases with the interval between 
diagnosis and starting treatment, particularly for patients 
who initiate treatment in adulthood. In the older ATI 
cohorts, the longer time interval between diagnosis and 
treatment initiation could be indicative of GD patients 
with less severe hematological and visceral manifesta-
tions or they may have had a longer interval because 
they were diagnosed prior to the era when treatment was 
available. They then have a higher risk of fracture, pos-
sibly due to the progressive onset of “silent” bone disease 
manifestations in the absence of treatment.
GD1 patients with a history of total splenectomy prior 
to initiation of ERT are more prone to development of 
many late-onset complications including bone marrow 
failure, portal and pulmonary hypertension, osteolytic 
lesions, osteonecrosis and osteopenia [28]. The per-
centage of splenectomized patients in each of the 3 ATI 
cohorts is higher in patients who experienced fractures 
than in those without fractures (Table  1). Splenectomy 
was statistically significantly associated with fracture risk 
only in the ≥ 18 to < 50 years ATI cohort (56% greater risk 
of fracture post-splenectomy). The association between 
splenectomy and fracture risk in the < 18  years ATI 
cohort was a 61% greater risk of fracture post-splenec-
tomy, but it did not reach statistical significance, possibly 
due to the small number of patients in this age group who 
had undergone splenectomy [26]. In the ≥ 50  years ATI 
cohort, the statistical analysis may have been affected by 
the exclusion of patients from the study population who 
may have experienced fractures during the long interval 
between the date of splenectomy and the date of initia-
tion of imiglucerase.
Being female is a significant factor in the ≥ 50  years 
ATI cohort with presumably the highest proportion of 
post-menopausal women. Sex was not a significant fac-
tor for either of the two younger ATI cohorts. Our esti-
mates of higher fracture risk in women compared to 
men over 50  years of age (approximately 2-fold) are in 
line with findings in the general population  [29]. These 
findings suggest that general risk factors for post-men-
opausal osteoporosis (e.g. smoking, family history) also 
contribute to the overall fracture risk in female patients 
with GD1. Women of Ashkenazi Jewish ancestry have 
also been identified as being at high risk for fracture [30]. 
Although no subset analyses were conducted looking at 
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ancestry due to the high proportion of patients without 
ancestry data reported in the Registry, women of Ashke-
nazi Jewish ancestry are a part of the population of this 
study and their risk is incorporated within the analyses 
for the GRAF score calculation. The refinement of the 
GRAF score with information about fracture risk in spe-
cific populations is a field for further study.
The GRAF score was significantly associated with frac-
ture risk within each ATI cohort. In all cohorts, each 
1-point increase in risk score was associated with a 2.7-
fold increased risk of first fracture (all types) in adult-
hood. There was an approximately 3- to 4-fold increased 
risk of spinal fracture associated with a 1-point increase 
in risk score in all 3 ATI cohorts. The GRAF score was 
moderately successful in predicting fracture across 
the 3 ATI cohorts, as indicated by the integrated AUC 
(0.62, 0.64, 0.65). The results are comparable to AUC of 
the FRAX tool with post-menopausal women, both for 
FRAX and hip BMD (0.66 [95% CI 0.60–0.73]) and for 
FRAX alone (0.63 [95% CI 0.56–0.69]) [31, 32].
The cumulative incidence function plots illustrate the 
increasing probability of fracture over time based upon 
whether a patient’s risk score falls in the lower, middle, 
or upper third of the GRAF score distribution within 
each ATI cohort. The probability of fracture continually 
increases over the years of follow up. It does not plateau 
early after the start of ERT despite the fact that maxi-
mal hematological and visceral therapeutic responses 
are achieved within 5  years of initiation of treatment 
[33]. Significant differences in the cumulative incidence 
functions across the GRAF score tertiles were observed 
within the two older ATI cohorts, with the highest risk 
tertile appearing to have the greatest separation from 
the lower tertiles. The < 18 year ATI cohort did not show 
statistically significant differentiation among the tertiles; 
the moderate and high risk tertiles in this cohort appear 
to have the most similar trajectories. The scores that 
define each tertile within each ATI cohort are presented 
in Fig. 2. The instructions for calculating the risk score of 
individual patients are presented in supplemental materi-
als (Additional file 1: S-I).
Although the GRAF score is derived from data of 
treated patients, the most appropriate time to apply the 
score may be at the decision point of initiating therapy. 
The age at treatment initiation and the interval between 
diagnosis and treatment initiation are important factors 
in the calculation. The physician faced with a treatment 
decision could apply the score based on the alternative 
assumptions that GD-specific treatment starts now (with 
current age and interval since diagnosis) or is deferred to 
a specific later date (when age and interval between diag-
nosis and start of treatment are clearly greater). The risk 
of post-treatment fracture under both scenarios may help 
the physician decide whether to recommend starting 
treatment or continue careful observation. However, the 
increased risk of fracture for those patients with a larger 
interval between diagnosis and treatment may also indi-
cate that progressive skeletal disease has occurred dur-
ing the untreated interval and delaying treatment further 
would not be indicated. A worked example is presented 
in supplementary materials (Additional file  1: S-I). The 
GRAF score addresses the association of deferment of 
treatment on the post-treatment risk for fractures. The 
score does not address the risk of fracture during any 
pre-treatment period, during which fracture risk is more 
appropriately estimated with serial DXA with or without 
FRAX scoring. Finally, there may be many other reasons 
besides fracture risk to treat GD; a low GRAF score alone 
does not necessarily indicate that treatment should be 
deferred.
The methodology behind the GRAF score is robust. 
The analyses show the impact of each factor while adjust-
ing for all the other relevant factors, rather than estimat-
ing the association for each individual factor separately. 
Consequently, the GRAF score, which is calculated using 
the β estimates from the multivariable Cox proportional 
hazards regression (Additional file 1: S-I), is not a simple 
count of the number of risk factors. Instead it incorpo-
rates a weighting of each factor according to the strength 
of its association (i.e. the regression coefficient) with frac-
ture risk. Patient age is an established risk factor for frac-
ture [23, 24]. The GRAF score accounts for the increasing 
risk of fracture with age by stratifying patients within 
similar-aged peer groups based on age at treatment initi-
ation and by including age at treatment initiation as a risk 
factor within each ATI cohort. The plots of the probabil-
ity of fracture over time based on categories (i.e., lower, 
middle, and upper tertiles) of the GRAF score aid in the 
clinical interpretation of fracture probability for patients 
who fall into a certain GRAF score category. Using the 
instructions, equation, and β weights provided in sup-
plemental materials (Additional file 1: S-I), a clinician can 
calculate a GRAF score for an adult, fracture-free patient 
based upon his or her age and select characteristics at 
treatment initiation. The probability of fracture over time 
can then be approximated using the cumulative incidence 
plots derived from the ICGG Gaucher Registry data.
Our study has limitations. The ICGG Gaucher Regis-
try has enrolled a large international pool of over 6000 
GD patients and has collected longitudinal data since 
1991. However, it is a voluntary, observational database 
and missing data can be problematic. For this analy-
sis, data sets are complete for all 3216 eligible patients. 
However, many patients were excluded because of 
incomplete diagnostic information or missing data 
about splenectomy status. We cannot be certain that 
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these exclusions do not impact our results. We also 
cannot verify that all fracture events were reported 
to the Registry or that all fractures were due to fragil-
ity rather than excessive trauma. Data about concur-
rent illnesses, physical activity, history of falls, frailty, 
smoking, alcohol and drug use, family history of oste-
oporosis, and use of concurrent medications includ-
ing anti-resorptive agents and vitamin D supplements 
might have been incorporated to improve the sensitiv-
ity and predictive ability of the GRAF score. However, 
this information is not collected in the ICGG Gaucher 
Registry. ERT dose was also not included in the score 
calculation due the complexity and potential incom-
pleteness of the dose data. Attempting to incorporate 
all of these factors might also have rendered the GRAF 
score too complex for routine clinical use.
Because this study was restricted to patients treated 
with alglucerase and/or imiglucerase, we cannot assure 
that the GRAF score will necessarily be comparable 
for patients treated with other ERTs. In our study, 50 
of all 288 first-time fractures (17%) occurred after a 
switch from imiglucerase to an alternative treatment. 
The impact of switching treatment on fracture risk is 
not known. No long-term head-to-head studies have 
been completed to support the hypothesis that there is 
no difference in therapeutic efficacy between imigluc-
erase, velaglucerase alfa and taliglucerase alfa. We are 
not aware of published data from the Gaucher Out-
come Survey that primarily follows patients initially 
treated with velaglucerase regarding occurrence of 
fractures or osteonecrosis in its GD1 population. Pend-
ing such information, it seems likely to propose that 
GRAF scoring could reasonably be applied regardless 
of ERT choice [34]. Determining whether the GRAF 
score will accurately forecast fracture risk in treatment-
naïve patients who are started on alternative, allegedly 
more bone-penetrant GD treatments (e.g., oral, small 
molecule substrate synthesis inhibitors) in adult GD1 
patients will be of interest.
Conclusions
The GRAF score is a tool to be used with bone density 
measurement and other modifiable, non-GD-specific risk 
factors (e.g., smoking, alcohol intake, frailty) to inform 
physicians and previously untreated GD1 patients about 
risk for a future fracture after starting imiglucerase or 
presumably, other alternative ERTS. GRAF scoring can 
also help predict the extent that fracture risk increases 
if initiation of treatment is deferred by either physician 
judgment or patient choice. Better prevention of serious 
bone complications is currently recognized as an unmet 
need for patients with GD1 [35]. When considering 
initiation of treatment, it is useful to know to what extent 
fixed patient-specific factors determine risk for future 
fractures beyond standard risk factors that change with 
time and treatment such as decreased bone mineral den-
sity. As similar risk factors determine the risk of post-
treatment osteonecrosis [27], a risk-score based on the 
principles outlined in this paper could be applied to the 
likelihood of major bone events occurring: a combination 
of fracture and osteonecrosis, the two most impactful 
and feared complications of GD.
Methods
The ICGG Gaucher Registry
The ICGG Gaucher Registry is a voluntary, global, 
observational database with enrollment of over 6000 
GD patients from more than 60 countries [36]. Patients’ 
treating physicians determine clinical assessments and 
care of enrolled patients, and the physicians voluntarily 
provide data on assessments of the clinical manifesta-
tions, GD progression and response to therapy.
This study was conducted according to the principles of 
the Declaration of Helsinki (2013) [37]. Informed consent 
was obtained from all subjects at the time of enrollment 
in the Registry. The data are reported in accordance with 
STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) guidelines [38].
Study population
Patients included in the study met all of the following 
criteria: (1) diagnosed with GD1 as determined by the 
participating Registry physician, (2) a known diagnosis 
date, a recorded birthdate, and a last follow-up date, (3) 
first primary therapy was imiglucerase, (4) had known 
splenectomy status and, if splenectomized, the date of 
the splenectomy was recorded, (5) at least one skeletal 
assessment recorded, and (6) if a fracture was reported, a 
date of fracture was recorded. All patients who met these 
inclusion criteria comprised the total study population 
for descriptive analyses.
For the risk factor analysis population, the sample 
was limited to patients with first fractures occurring 
after imiglucerase treatment initiation and in adulthood 
(age ≥ 18  years) as well as patients who did not experi-
ence a fracture during follow-up. Patients whose follow-
up ended prior to 18  years of age or who experienced 
a fracture prior to treatment initiation or in childhood 
(age < 18 years) were excluded from the risk factor analysis.
Definition of age at treatment initiation (ATI cohorts)
Patients were classified into 3  ATI cohorts based upon 
the age range of imiglucerase treatment initiation: 1) 
prior to 18  years of age, 2) between ≥ 18 and < 50  years, 
3) ≥ 50  years of age. These age cohorts have been used 
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in previous studies [26], including a GD1 bone study of 
the effect of alendronate sodium [39], and are designed 
to distinguish patients who began treatment early (dur-
ing childhood or adolescence) as well as to distinguish 
women of post-menopausal age by using age ≥ 50  years 
as a proxy.
Individual risk factors
Factors considered for inclusion in the analyses were 
based on the potential relationship with fracture and the 
availability and completeness of the data in the ICGG 
Gaucher Registry. Factors that met these criteria were 
sex, age at treatment initiation, time interval between 
diagnosis and treatment initiation, splenectomy status 
at treatment initiation, and history of bone crisis prior to 
treatment initiation. Sex was included due to the greater 
risk of fracture for post-menopausal women [18, 40]. The 
interval between diagnosis and treatment initiation has 
been associated with avascular necrosis [27] and may 
potentially be related to fracture risk. Splenectomy status 
was included because of lower bone density in those who 
have been splenectomized [41].
Other factors not in the current analysis include ane-
mia (previous studies showed an association with avas-
cular necrosis but not fracture [5]) and bone pain (there 
is no standardized scale between different centers, and 
bone pain and bone crisis are also highly correlated). 
Genotype was included initially but was not signifi-
cant for any ATI cohort (data not shown) and was not 
included in the final model.
The importance of DXA BMD measurement for 
assessing hip and vertebral fracture risk specifically 
in patients with GD1 is well documented [5, 42, 43]. 
Because the GRAF score is static and subject to change 
only if treatment is not initiated at the time of calcula-
tion, it is intended to be used prior to DXA to assist the 
clinician with assessing to what extent the fracture risk 
will increase with additional delay and help the clinician 
with strategies to reduce risk of fracture. These strate-
gies may include avoiding splenectomy, minimizing the 
time between diagnosis and treatment, considering the 
needs to optimize bone health in higher risk groups such 
as post-menopausal women, and treatment initiation 
prior to development of bone crises. Bone density from 
DXA rather than the GRAF score is more appropriate 
for assessing response and changing fracture risk after 
treatment initiation. For this reason, we decided not to 
attempt to incorporate the DXA or FRAX score into the 
GRAF.
Derivation of the GRAF score
Cox proportional hazards regression was used to derive 
beta (β) coefficients for risk of first fracture (all types) 
separately by ATI cohort. Multivariable models included 
the 5 individual risk factors: sex (male, female), age at 
imiglucerase initiation (in years), time interval between 
diagnosis and imiglucerase initiation (in years), splenec-
tomy status at treatment initiation (splenectomized, not 
splenectomized), and bone crisis ever reported prior 
to treatment initiation (yes, no). An additive summary 
risk score was calculated for each of the ATI cohorts by 
weighting the value of each risk factor by the correspond-
ing β coefficient from the Cox model, where β represents 
the strength of the association for a particular risk fac-
tor. Additional details for calculating the risk score for 
an individual patient within a certain ATI cohort are 
described in supplemental material (Additional file  1: 
S-I).
Statistical analyses
Descriptive analyses of demographic and clinical charac-
teristics of patients with pediatric and adult first fractures 
and the distribution of fracture locations were conducted 
among the total study population. In addition, demo-
graphic and clinical characteristics of patients eligible for 
the risk factor analysis (i.e. patients who were fracture-
free at baseline) were described. Baseline was defined as 
age 18 years for patients who initiated imiglucerase treat-
ment < 18  years and as the date of imiglucerase initia-
tion for patients who initiated treatment ≥ 18 years. The 
occurrence of multiple fractures on the first fracture date 
or subsequent fractures was also described among the 
risk factor analysis population.
For the analysis of individual risk factors for each ATI 
cohort, Cox proportional hazard regression was used to 
evaluate the multivariable model containing the 5 indi-
vidual risk factors for risk of all types of fracture and 
then of spinal fractures separately. Patients were followed 
from baseline to the date of first fracture, death, or the 
last follow-up visit recorded, whichever occurred first. 
Patients may have switched or discontinued imiglucerase 
treatment during the follow-up period. Male was the ref-
erent category for sex. Splenectomy and bone crisis were 
scored as present or absent, with absence being the ref-
erent category. Age at treatment initiation and the time 
interval between diagnosis and treatment initiation were 
scaled to a 10-year interval for ease of interpretation; a 
10-year difference is more clinically meaningful than a 
1-year difference.
For the analysis of the GRAF score for each ATI cohort, 
Cox proportional hazard regression was used to evalu-
ate the association between the continuous GRAF score 
and fracture risk (all types and spinal fracture). Patients 
were then classified into tertiles of risk score to plot the 
cumulative incidence of first fracture (all types) over 
time within each ATI cohort; Gray’s test was used to 
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test whether the cumulative incidence function varied 
by risk score tertile. An integrated area under the ROC 
curve (AUC) was calculated to assess the ability of the 
risk score to classify patients by fracture status. The inte-
grated AUC is a summary measure of the AUCs over the 
entire time period, which does not have the option of 
providing 95% confidence intervals (CI).
The primary hypothesis test for the association of 
GRAF score with fracture risk (all types) was two-tailed 
with an alpha level of 0.05, performed separately by ATI 
cohort. The association of GRAF score with spinal frac-
ture risk was exploratory, so p-values were not corrected 
for multiple comparisons. Statistical analyses were con-
ducted using the SAS software version 9.4 (Cary, North 
Carolina).
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